Two FDA Peptide announcements. July 2026. A lot of confusion.
There were two completely separate FDA peptide actions in late July 2026. A lot of coverage is blending them together, but they involve different peptides, different regulatory processes and different outcomes.
1. July 23-24: FDA advisory panel vote on compounded peptides
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed 7 peptides for possible inclusion on the 503A Bulks List, which determines which substances compounding pharmacies may eventually be allowed to use.
The panel recommended 6 of the 7:
The only rejection was Emideltide (DSIP).
What's unusual is that FDA career scientists recommended against every peptide, but the panel voted the opposite way. The votes were close, with BPC-157, KPV and TB-500 each passing 8-6 with one abstention.
Nothing changes legally yet. The vote is nonbinding. None of these peptides are FDA approved or on the 503A Bulks List. FDA would still need to accept the recommendations and complete formal rulemaking before anything changes, a process that could take well into 2027 or 2028.
2. July 28: FDA generic peptide guidance
Five days later, FDA published 17 revised draft Product-Specific Guidances (PSGs) covering 9 FDA-approved peptide drugs, including:
These guidances tell generic drug manufacturers how to develop abbreviated new drug applications. They do not legalize peptides, approve new therapies or affect compounded peptides.
FDA also quietly withdrew a 2021 synthetic peptide guidance, saying it no longer reflects the agency's current scientific thinking. A replacement is planned later this year.
Why people are mixing them up
A KTVU FOX 2 article discussing the PCAC vote linked readers to the FDA announcement about the generic PSGs.
That created confusion because the two actions share no overlapping compounds.
The advisory panel considered BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon.
The FDA guidance covers approved medicines like semaglutide, tirzepatide and liraglutide.
They are separate regulatory actions that happened five days apart.
July 23-24: FDA advisers recommended six peptides for possible future inclusion on the 503A Bulks List, against FDA staff recommendations. Nothing changes legally yet.
July 28: FDA updated generic drug guidance for approved peptide medicines and withdrew an older peptide guidance.
They are not the same story, even though many articles have blurred the distinction.
For all the latest unbiased research-backed information on peptides, dosage, protocol, and research without the internet hype, visit onpeps.com.